Paper Details

  1. Home
  2. Paper Details

[Results of a double-blind study comparing the effects of timolol and pilocarpine in 110 patients with chronic open-angle glaucoma].

Author: ChagnonA, HamardH, OurgaudA G, PlaneC, SoleP, VidalR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Timolol administered twice daily provided satisfactory intraocular pressure control in 81.8% of patients with open-angle glaucoma, compared to only 41.8% of patients treated with pilocarpine. Timolol was associated with fewer side effects than pilocarpine.
Paper Details　
Original Abstract of the Article :
Following a seventeen weeks study including 110 patients with open-angle glaucoma, 81,8% of the patients treated by timolol, administered twice a day, had a satisfactory control of their intraocular pressure, against only 41,8% of those patients treated by pilocarpine, administered four times a day....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/155098

データ提供：米国国立医学図書館（NLM）

Results of a Double-Blind Study Comparing the Effects of Timolol and Pilocarpine in 110 Patients with Chronic Open-Angle Glaucoma

Glaucoma, a leading cause of irreversible blindness, requires careful management to control intraocular pressure (IOP). This double-blind study aimed to compare the effectiveness of two commonly used IOP-lowering medications, timolol and pilocarpine, in patients with chronic open-angle glaucoma. The study enrolled 110 patients and monitored their IOP over a 17-week period. The results showed that timolol, administered twice daily, achieved satisfactory IOP control in a significantly higher proportion of patients (81.8%) compared to pilocarpine, administered four times daily (41.8%). The authors also noted that timolol had fewer clinically significant side effects compared to pilocarpine, which is known to cause a range of subjective and objective symptoms.

Timolol: A Superior Option for IOP Control

The study's findings demonstrate the superiority of timolol over pilocarpine in controlling IOP in patients with chronic open-angle glaucoma. The significantly higher success rate of timolol, coupled with its favorable side effect profile, make it a more desirable treatment option for this patient population.

Optimizing Glaucoma Management

The study provides valuable information for ophthalmologists seeking to optimize glaucoma management. The authors' findings highlight the importance of selecting appropriate medications based on their efficacy and side effect profiles. The choice between timolol and pilocarpine should be carefully considered, taking into account the individual patient's needs and preferences.

Dr.Camel's Conclusion

This study is a beacon of light in the desert of glaucoma research, demonstrating the effectiveness of timolol in controlling IOP. The authors' findings provide a valuable roadmap for ophthalmologists, highlighting the importance of selecting the most appropriate medication for each patient. It's a testament to the power of research in guiding clinical decision-making and improving patient outcomes.

Date :
  1. Date Completed 1979-06-26
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

155098

DOI: Digital Object Identifier

155098

SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.